Link between muscle loss and nerve damage in adults with type 1 diabetes
Official title: Association Between Sarcopenia And Diabetic Neuropathy In Adults With Type 1 Diabetes, A Pilot Study
Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06902597 · Data updated 2026-11-12
This study is testing how muscle loss and nerve damage are related in adults aged 50-80 with type 1 diabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Rome, Lazio) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | January 31, 2026 |
| Study ends | January 31, 2026 |
| Registry record updated | March 30, 2025 |
| Trial ID | NCT06902597 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 50-80 with a diagnosis of type 1 diabetes for at least 10 years.
✕Probably not a fit
Patients with type 2 diabetes or significant comorbidities such as heart failure or neurodegenerative diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to evaluate the prevalence of sarcopenia, which is the loss of muscle mass, in adults aged 50-80 with type 1 diabetes. It will also investigate the association between diabetic neuropathy, a common complication of diabetes, and sarcopenia in this population. Participants will undergo dual energy X-ray absorptiometry to assess their muscle mass and strength. The study seeks to provide insights into how these two conditions may be interconnected in individuals with long-standing type 1 diabetes.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of muscle loss and nerve damage in patients with type 1 diabetes.
How similar studies have gone: While the association between sarcopenia and diabetic neuropathy is a relatively novel area of investigation, similar studies have indicated potential links between muscle health and diabetes complications.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 50-80 years, both sexes 2. Diagnosis of T1DM for at least 10 years, in both multiple daily injections of insulin (MDI) and continuous subcutaneous insulin infusion (CSII) 3. Informed consent before any study activity 4. Ability to fully perform all protocol activities Exclusion Criteria: 1. Previous diagnosis of T2DM 2. Previous diagnosis of dementia 3. Presence of heart failure (NYHA class III and IV) 4. Presence of muscular disease 5. Diagnosis of neurodegenerative disease (e.g. multiple sclerosis, Parkinson's disease) 6. eGFR evaluated through CKD-EPI formula \<20 ml/min /1.73m2 , estimated on previous creatinine dosage 7. Previous history of stroke or cerebrovascular disease 8. Diagnosis of coeliac disease 9. Diagnosis of chronic inflammatory bowel disease 10. Untreated hypothyroidism or hyperthyroidism or not well controlled hypothyroidism or hyperthyroidism with current therapy (TSH \>5 or TSH \<0.15) 11. Alcohol abuse or consumption of more than 14 alcoholic units weekly 12. Active cancer or therapy 13. Pregnancy 14. Primary hyperparathyroidism 15. Corticosteroid and/or estrogen-progestogen therapy for at least 12 months in medical history 16. On going treatment with antiretroviral therapy 17. On going treatment with immunosuppressive therapy, e.g. cyclosporine, tacrolimus 18. On going treatment with anti-epileptic drugs
Where it's running
-
Fondazione Policlinico Universitario A. Gemelli IRCCS; UOC Diabetologia
Rome, Lazio, Italy Recruiting
Study contacts
- Principal investigator: Dario Pitocco — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Dario Pitocco
- Email: dario.pitocco@policlinicogemelli.it
- Phone: +39 0630154071
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity
This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.
-
Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes
This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.
-
CGM-guided carb awareness education for adults with Type 1 diabetes
This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.
-
Safety and effectiveness of GLP-1 receptor agonists and SGLT inhibitors added to insulin in adults with type 1 diabetes
This registry will see if adding GLP-1RA or SGLTi therapies to insulin helps adults with type 1 diabetes over one year.
-
Think-Find-Solve activities for insulin self-management in children with type 1 diabetes
A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.